KBC Group
DYN icon

KBC Group’s Dyne Therapeutics DYN Stock Holding History

KBC Group’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76K Hold
3,405
– – ﹤0.01% 1552
2026
Q1 		$62K Buy
3,405
+270
+9% +$4.66K ﹤0.01% 1570
2025
Q4 		$61K Hold
3,135
– – ﹤0.01% 1564
2025
Q3 		$40K Hold
3,135
– – ﹤0.01% 1694
2025
Q2 		$30K Hold
3,135
– – ﹤0.01% 1701
2025
Q1 		$33K Hold
3,135
– – ﹤0.01% 1846
2024
Q4 		$74K Buy
3,135
+978
+45% +$28.9K ﹤0.01% 1709
2024
Q3 		$77K Buy
2,157
+751
+53% +$29.9K ﹤0.01% 1456
2024
Q2 		$50K Hold
1,406
– – ﹤0.01% 1611
2024
Q1 		$40K Buy
+1,406
New +$31.8K ﹤0.01% 1667

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

KBC Group's DYN Position: Q2 2026 in Review

KBC Group held its Dyne Therapeutics (DYN) position steady in Q2 2026 at 3,405 shares worth $76K. The position accounts for ﹤0.01% of the portfolio, ranked #1552.

KBC Group first reported a position in DYN in Q1 2024 and has held it in 10 quarters since. The position peaked at $77K in Q3 2024. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • KBC Group held 3,405 shares of Dyne Therapeutics worth $76K as of Q2 2026.
  • KBC Group left its Dyne Therapeutics share count unchanged in Q2 2026.
  • Dyne Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1552 holding.
  • KBC Group first reported a position in Dyne Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • KBC Group's Dyne Therapeutics position peaked at $77K in Q3 2024.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.